Incyte has reported new 52-week data from a Phase II trial of oral JAK1 inhibitor, povorcitinib (formerly INCB54707), in adult hidradenitis suppurativa (HS) patients.

The double-blind, dose-ranging, randomised, placebo-controlled Phase II trial was designed for assessing the safety and efficacy of povorcitinib in these patients.

Findings showed that longer-term treatment with povorcitinib 75mg once daily (QD) resulted in sustained and durable efficacy across all treatment arms.

They include the 36-week open-label extension period during which all participants who have received povorcitinib 75mg QD demonstrated sustained efficacy for all treatment arms after switching to this dose.

At week-52, the oral inhibitor also showed durable efficacy in high-threshold outcomes.

It was also found to be generally well tolerated and showed a safety profile that is consistent with the previous data.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Incyte Drug Development, Inflammation & AutoImmunity associate vice-president and Povorcitinib global programme head Kurt Brown said: “HS is a chronic, progressive and debilitating condition for which there is no cure.

“We are encouraged by these Phase II data and believe they reinforce the potential of povorcitinib to be a safe and efficacious treatment for HS that is tolerable with longer-term administration, even at the higher doses.

“Despite the available treatments for HS, no uniformly effective therapy has been found, underscoring the need for additional options. We look forward to continuing to progress the development of povorcitinib through our ongoing Phase III trial in patients with moderate-to-severe HS.”

Upper respiratory tract infection, urinary tract infection, nasopharyngitis, increased blood creatine kinase (CK), Covid-19, headache, and acne were the most common treatment-emergent adverse events observed at week-52.